sb 203580 has been researched along with Granulocytic Leukemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Birkenkamp, KU; Esselink, MT; Kruijer, W; Vellenga, E | 1 |
| Honma, Y; Ishii, Y; Sakai, S | 1 |
| Babbin, BA; Bryington, M; Dangsupa, A; Hu, X; Janssen, WE; Moscinski, LC; Rezai-Zadeh, N; Zuckerman, KS | 1 |
| Kucera, GL; Stadheim, TA | 1 |
4 other study(ies) available for sb 203580 and Granulocytic Leukemia
| Article | Year |
|---|---|
Differential effects of interleukin-3 and interleukin-1 on the proliferation and interleukin-6 protein secretion of acute myeloid leukemic cells; the involvement of ERK, p38 and STAT5.
Topics: Acute Disease; Cell Division; DNA; DNA-Binding Proteins; Flavonoids; Humans; I-kappa B Proteins; Imidazoles; Interleukin-1; Interleukin-3; Interleukin-6; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; MAP Kinase Signaling System; Milk Proteins; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Protein Binding; Protein Serine-Threonine Kinases; Pyridines; STAT5 Transcription Factor; Trans-Activators; Transcriptional Activation; Tumor Cells, Cultured | 1999 |
Pyridinyl imidazole inhibitor SB203580 activates p44/42 mitogen-activated protein kinase and induces the differentiation of human myeloid leukemia cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Differentiation; Cell Division; Enzyme Activation; HL-60 Cells; Humans; Imidazoles; Leukemia, Myeloid; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pyridines; Tumor Cells, Cultured | 2001 |
An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism.
Topics: Activating Transcription Factor 2; Anti-Infective Agents; Apoptosis; Cyclic AMP Response Element-Binding Protein; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Humans; I-kappa B Proteins; Imidazoles; Leukemia, Myeloid; MAP Kinase Kinase Kinase 1; Mitogen-Activated Protein Kinases; Necrosis; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Sulfones; Transcription Factors; Tumor Cells, Cultured; U937 Cells | 2001 |
c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells.
Topics: Anisomycin; Antineoplastic Agents; Apoptosis; Blotting, Western; DNA, Neoplasm; Flavonoids; HL-60 Cells; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mitoxantrone; p38 Mitogen-Activated Protein Kinases; Precipitin Tests; Protein Synthesis Inhibitors; Pyridines; Transfection | 2002 |